ESTRO 2021 Abstract Book

Poster highlights Poster Highlights 3: Outcome modelling.......................................................................................................(abs. 103 - 109) Poster Highlights 4: Lower GI (colon, rectum, anus)......................................................................................(abs. 110 - 116) Plenary session Presidential symposium - Optimal radiotherapy for all................................................................................(abs. 117 - 121) Symposium Guidelines..........................................................................................................................................................(abs. 122 - 129) Radiobiology underpinning the interactions between radiotherapy and the anti-tumour immune response.............................................................................................................................................(abs. 130 - 133) Debate Should the majority of radiation treatments after breast conserving surgery consist of maximum 5 fractions?... (abs. 134 - 138) Joint symposium ESTRO-CARO: COVID-19....................................................................................................................................(abs. 139 - 143) Symposium Proton arc therapy - An evolution or revolution?...........................................................................................(abs. 144 - 146) The use of MR in radiotherapy.........................................................................................................................(abs. 147 - 149) What’s next for breathing motion management in radiotherapy?...............................................................(abs. 150 - 152) Joint symposium ESTRO-ESGO - State of the Art: Updated ESGO-ESTRO-ESP guidelines in endometrial cancer.................(abs. 153 - 158) Poster highlights Poster Highlights 5: Advanced radiotherapy service implementation.........................................................(abs. 159 - 164) Poster Highlights 6: CNS 1................................................................................................................................(abs. 165 - 171) Award lecture E van der Schueren Award. ..............................................................................................................................(abs. 172 - 173) Jens Overgaard Legacy Award..........................................................................................................................(abs. 174 - 175) Proffered papers Proffered papers 8: Patient-reported outcome measures & quality of life.................................................(abs. 176 - 181) Proffered Papers 9: Radiation immune effects..............................................................................................(abs. 182 - 187) Proffered papers 10: Lung................................................................................................................................(abs. 188 - 193) Proffered papers 11: Detectors and dosimetry..............................................................................................(abs. 194 - 199) Proffered papers 12: Adaptive RT: Proton......................................................................................................(abs. 200 - 205) Proffered papers 13: Haematology / Paediatrics / Sarcoma.........................................................................(abs. 206 - 211) Poster highlights Poster Highlights 7: Quantitative functional and biological imaging...........................................................(abs. 212 - 218) Poster Highlights 8: Breast...............................................................................................................................(abs. 219 - 225)

SUNDAY 29 AUGUST 2021

Teaching Lecture Biomarker-guided precision radiotherapy............................................................................................................... (abs. 226) The radiobiology of the normal brain...................................................................................................................... (abs. 227) Shifting cold to hot tumors: Interplay between radiation, cancer cells and microenvironment........................ (abs. 228) How to tailor your cervical cancer treatment based on evidence-based dose-effect relationships.........(abs. 229 - 230) IAEA TRS 398: Update for modern radiotherapy..................................................................................................... (abs. 231) The dos and don’ts for statistical treatment outcome modelling......................................................................... (abs. 232) The future of RTT advanced practice........................................................................................................................ (abs. 233) Symposium Turning cold into hot tumours: Challenges in radio-immunotherapy.........................................................(abs. 234 - 236) Normal tissue effects of combined therapies................................................................................................(abs. 237 - 240)